Clinitech laboratory Limited has announced a significant operational change regarding its market maker arrangement. The Board of Directors approved the transition from SVCM Securities Private Limited to Kalpalabdhi Financials Private Limited as the company's new market maker, effective April 10, 2026.

Board Resolution and Timeline

The Board of Directors passed the resolution for this change through circulation on April 09, 2026. The appointment of the new market maker becomes effective from April 10, 2026. This swift transition ensures minimal disruption to market making activities for the company's shares.

Reason for Market Maker Change

The change in market maker became necessary due to the discontinuation of services by SVCM Securities Private Limited. The existing market maker ceased its market making operations due to internal restructuring within the organization, with effect from April 09, 2026. This internal restructuring at SVCM Securities prompted Clinitech Laboratory to secure alternative market making arrangements.

Tripartite Agreement Details

A comprehensive tripartite agreement has been executed between three parties to formalize the new arrangement:

The agreement was executed on April 09, 2026, establishing the framework for the new market making arrangement.

Regulatory Compliance

Clinitech Laboratory Limited has committed to fulfilling all regulatory requirements associated with this change. The company will submit necessary applications to SEBI and the stock exchange within the prescribed time limit to update and intimate the change in market maker. This disclosure has been made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, ensuring transparency and compliance with regulatory obligations.

Market Making Agreement Structure

The nature of the agreement is classified as a Market Making Agreement, designed to ensure adequate liquidity and price discovery for Clinitech Laboratory's shares. The new arrangement with Kalpalabdhi Financials Private Limited is expected to maintain continuity in market making services following the transition from the previous provider.

Clinitech laboratory has filed its quarterly disclosure under SEBI Regulation 74(5) of the Depositories and Participants Regulations, 2018 for the quarter ended March 31, 2026. The disclosure, submitted to BSE Limited on April 07, 2026, confirms the company's compliance with dematerialisation requirements.

Quarterly Demat Status Report

The company's Registrar and Transfer Agent, Bigshare Services Pvt. Ltd., confirmed that SEBI Regulation 74(5) is not applicable to Clinitech Laboratory Limited during the quarter ended March 31, 2026. This exemption applies because the entire shareholding of the company remains in dematerialised form.

Regulatory Compliance Framework

The disclosure was signed by Chairman and Managing Director Jagdish Umakant Nayak on behalf of the company and submitted with proper digital authentication. The certificate from Bigshare Services Pvt. Ltd. was dated April 06, 2026, and subsequently forwarded to BSE Limited on April 07, 2026.

Previous Compliance Activities

This filing follows the company's earlier submission of its annual disclosure under SEBI Regulation 31(4) for FY26, which was filed on April 06, 2026. The previous disclosure confirmed that no encumbrance was made over shares held by promoters and persons acting in concert during the financial year.

Documentation Details

The quarterly disclosure includes confirmation from the company's RTA that no shareholders requested conversion of their dematerialised shares back to physical form during the reporting period. This status maintains the company's full compliance with modern securities trading requirements, where all shares remain in electronic format for efficient trading and settlement.